FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3126988422> ?p ?o ?g. }

• W3126988422 endingPage "475" @default.
• W3126988422 startingPage "457" @default.
• W3126988422 abstract "Cholangiocarcinoma (CCA) is the second most common hepatobiliary cancer and associated with a poor prognosis. Only one-third of CCA cases are diagnosed at operable stages. However, a high rate of relapse has been observed postoperatively. Besides screening for operable individuals, efficacious therapeutic for recurrent and advanced CCA is urgently needed. The treatment outcome of available therapeutics is important to clarify clinical indication and facilitate the development of treatment strategies.This review aims to compare the treatment outcome of different therapeutics based on both overall survival and progression-free survival.Over one hundred peer-reviewed articles were examined. We compared the treatment outcome between different treatment methods, including tumor resection with or without postoperative systematic therapy, chemotherapies including FOFLOX, and targeted therapies, such as IDH1, K-RAS, and FGFR inhibitors. Notably, the scientific basis and outcome of available treatment methods were compared with the standard first-line therapy.CCAs at early stages should firstly undergo tumor resection surgery, followed by postoperative treatment with Capecitabine. Chemotherapy can be considered as a preoperative option for unresectable CCAs. Inoperable CCAs with genetic aberrances like FGFR alterations, IDH1, and KRAS mutations should be considered with targeted therapies. Fluoropyrimidine prodrug (S-1)/Gemcitabine/Cisplatin and nab-Paclitaxel/Gemcitabine/Cisplatin show favorable outcome which hints at the triplet regimen to be superior to Gemcitabine/Cisplatin on CCA. The triplet chemotherapeutic should be tested further compared to Gemcitabine/Cisplatin among CCAs without genetic alterations. Gemcitabine plus S-1 was recently suggested as the convenient and equivalent standard first-line for advanced/recurrent biliary tract cancer.This review provides a comparative outcome between novel targeted therapies and currently available therapeutics." @default.
• W3126988422 created "2021-02-15" @default.
• W3126988422 creator A5020099143 @default.
• W3126988422 creator A5026070107 @default.
• W3126988422 creator A5027965195 @default.
• W3126988422 creator A5038081584 @default.
• W3126988422 creator A5090079195 @default.
• W3126988422 date "2021-07-01" @default.
• W3126988422 modified "2023-10-17" @default.
• W3126988422 title "Cholangiocarcinoma Therapeutics: An Update" @default.
• W3126988422 cites W143651898 @default.
• W3126988422 cites W1529734028 @default.
• W3126988422 cites W1596848781 @default.
• W3126988422 cites W1779300534 @default.
• W3126988422 cites W1861063348 @default.
• W3126988422 cites W1960850967 @default.
• W3126988422 cites W1963570372 @default.
• W3126988422 cites W1965716049 @default.
• W3126988422 cites W1968690354 @default.
• W3126988422 cites W1970020295 @default.
• W3126988422 cites W1970368087 @default.
• W3126988422 cites W1974564771 @default.
• W3126988422 cites W1975836447 @default.
• W3126988422 cites W1978614884 @default.
• W3126988422 cites W1979296768 @default.
• W3126988422 cites W1982288880 @default.
• W3126988422 cites W1988357374 @default.
• W3126988422 cites W1988476050 @default.
• W3126988422 cites W1993605227 @default.
• W3126988422 cites W1998759761 @default.
• W3126988422 cites W1999437680 @default.
• W3126988422 cites W2003753299 @default.
• W3126988422 cites W2005036868 @default.
• W3126988422 cites W2008837727 @default.
• W3126988422 cites W2011387799 @default.
• W3126988422 cites W2015613033 @default.
• W3126988422 cites W2018041848 @default.
• W3126988422 cites W2018709566 @default.
• W3126988422 cites W2018740895 @default.
• W3126988422 cites W2025590891 @default.
• W3126988422 cites W2027239974 @default.
• W3126988422 cites W2028415754 @default.
• W3126988422 cites W2028700227 @default.
• W3126988422 cites W2029572375 @default.
• W3126988422 cites W2033930383 @default.
• W3126988422 cites W2034770797 @default.
• W3126988422 cites W2038440796 @default.
• W3126988422 cites W2041941116 @default.
• W3126988422 cites W2058770031 @default.
• W3126988422 cites W2068447729 @default.
• W3126988422 cites W2069738597 @default.
• W3126988422 cites W2079892049 @default.
• W3126988422 cites W2081994793 @default.
• W3126988422 cites W2083472544 @default.
• W3126988422 cites W2086252871 @default.
• W3126988422 cites W2089003622 @default.
• W3126988422 cites W2091880724 @default.
• W3126988422 cites W2093959650 @default.
• W3126988422 cites W2093996140 @default.
• W3126988422 cites W2096796171 @default.
• W3126988422 cites W2107977954 @default.
• W3126988422 cites W2108756633 @default.
• W3126988422 cites W2115261608 @default.
• W3126988422 cites W2117834374 @default.
• W3126988422 cites W2125338608 @default.
• W3126988422 cites W2129296414 @default.
• W3126988422 cites W2141042450 @default.
• W3126988422 cites W2141078344 @default.
• W3126988422 cites W2143881980 @default.
• W3126988422 cites W2151660860 @default.
• W3126988422 cites W2158551726 @default.
• W3126988422 cites W2161608625 @default.
• W3126988422 cites W2165043263 @default.
• W3126988422 cites W2180850028 @default.
• W3126988422 cites W2229729310 @default.
• W3126988422 cites W2282307268 @default.
• W3126988422 cites W2301066876 @default.
• W3126988422 cites W2405916890 @default.
• W3126988422 cites W2465521803 @default.
• W3126988422 cites W2518904415 @default.
• W3126988422 cites W2522644647 @default.
• W3126988422 cites W2526881395 @default.
• W3126988422 cites W2531027579 @default.
• W3126988422 cites W2557092829 @default.
• W3126988422 cites W2560087117 @default.
• W3126988422 cites W2564810646 @default.
• W3126988422 cites W2578806339 @default.
• W3126988422 cites W2579286788 @default.
• W3126988422 cites W2589543707 @default.
• W3126988422 cites W2602621655 @default.
• W3126988422 cites W2604648767 @default.
• W3126988422 cites W2623089849 @default.
• W3126988422 cites W2725911379 @default.
• W3126988422 cites W2745230880 @default.
• W3126988422 cites W2750794123 @default.
• W3126988422 cites W2751131402 @default.
• W3126988422 cites W2752583521 @default.
• W3126988422 cites W2754809261 @default.

• next